eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2024-07-04 12 6 91 92 10.12691/ajmcr-12-6-3 AJMCR20241263 article Ashok Pandey dr.asokpandey@gmail.com 1 Arya Gautam 2 Medical Officer Urban Health Promotion Centre, Butwal, Nepal Intern Universal College of Medical Sciences, Nepal Background: Serratiopeptidase is an enzymatic drug that has anti-inflammatory and analgesic effects. Chronic pain at the site of vaccination is considered as an AEFI. In this report, we discuss a case of a 16-year-old female with chronic pain following vaccination and use of serratiopeptidase as an analgesic for her symptoms. Case Presentation: A 16-year-old female came to the primary health care center with pain in the left arm (over the deltoid region) followed by MR vaccination. On examination, there were no any neuromuscular deficits. Her pain was graded 6/10 according to the Numerical Rating Scale for pain. She was given serratiopeptidase for 10 days, which led to the resolution of her symptoms. Conclusion: Here, the case of chronic pain followed by vaccination is presented where the patient was prescribed with serratiopeptidase following failure to resolve her symptoms by other means. Despite the lack of any solid clinical evidence supporting its usage, patient outcome questions whether it is actually a potent analgesic or a placebo drug. https://pubs.sciepub.com/ajmcr/12/6/3/ajmcr-12-6-3.pdf Adverse event following immunization Chronic pain Measles-Rubella Vaccination Serratiopeptidase Analgesic